SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 1) *

Catalyst Pharmaceuticals, Inc.				
(Name of Issuer)				
Common Stock				
(Title of Class of Securities)				
14888U101				
(CUSIP Number)				
December 31, 2022				
(Date of Event Which Requires Filing of this Statement)				
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:				
□ Rule 13d-1(b)				
⊠ Rule 13d-1(c)				
☐ Rule 13d-1(d)				
(Page 1 of 9 Pages)				

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)				
	Deerfield Mgmt, L.P.				
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PL	ACE OF ORGANIZATION			
	Delaware				
	5.	SOLE VOTING POWER			
NUMBER OF		0			
SHARES	6.	SHARED VOTING POWER			
BENEFICIALLY OWNED BY		5,884,448 (1)			
EACH	7.	SOLE DISPOSITIVE POWER			
REPORTING PERSON					
WITH	8.	0 SHARED DISPOSITIVE POWER			
	0.				
9.	A CORECATE A MOU	5,884,448 (1)			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	5,884,448 (1)				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
	5.65%				
12.	TYPE OF REPORTING PERSON*				
	PN				

⁽¹⁾ Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

 1.	NAME OF REPORTIN	IC PERSONS			
1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)				
2.	Deerfield Management Company, L.P. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) □				
۷.	CHECK THE APPROI	SKIALE BOX IF A MEMIDER OF A GROUP	(a) □ (b) ⊠		
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PL	ACE OF ORGANIZATION			
	Delaware				
	5.	SOLE VOTING POWER			
NUMBER OF		0			
SHARES	6.	SHARED VOTING POWER			
BENEFICIALLY OWNED BY		5,884,448 (2)			
EACH REPORTING	7.	SOLE DISPOSITIVE POWER			
PERSON		0			
WITH	8.	SHARED DISPOSITIVE POWER			
	0.				
	1 00000 100 1000	5,884,448 (2)			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	5,884,448 (2)				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* □				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
	5.65%				
12.	TYPE OF REPORTING PERSON*				
	PN				
	1777				

⁽²⁾ Comprised of shares of common stock held by Deerfield Partners, L.P. of which Deerfield Management Company, L.P. is the investment advisor.

1.	NAME OF REPORTING PERSONS				
	I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)				
	Deerfield Partners, L.P.				
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				
			(b) ⊠		
3.	SEC USE ONLY				
4.	CITIZENSHIP OR PL	ACE OF ORGANIZATION			
	Delaware				
	5.	SOLE VOTING POWER			
NUMBER OF		0			
SHARES	6.	SHARED VOTING POWER			
BENEFICIALLY OWNED BY		5,884,448			
EACH	7.	SOLE DISPOSITIVE POWER			
REPORTING PERSON					
WITH	8.	0 SHARED DISPOSITIVE POWER			
	0.				
9.	ACCRECATE AMOU	5,884,448			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	5,884,448				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* □				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
	5.65%				
12.	TYPE OF REPORTING PERSON*				
	PN				

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)				
	James E. Flynn				
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				
3.	SEC USE ONLY				
4.	4. CITIZENSHIP OR PLACE OF ORGANIZATION United States				
	5.	SOLE VOTING POWER			
NUMBER OF		0			
SHARES	6.	SHARED VOTING POWER			
BENEFICIALLY OWNED BY		5 994 449 (2)			
EACH	7.	5,884,448 (3) SOLE DISPOSITIVE POWER			
REPORTING PERSON					
WITH	8.	0 SHARED DISPOSITIVE POWER			
	0.				
		5,884,448 (3)			
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	5,884,448 (3)				
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*				
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				
	5.65%				
12.	TYPE OF REPORTING PERSON*				
	IN				

⁽³⁾ Comprised of shares of common stock held by Deerfield Partners, L.P.

CUSIP No.	14888U101	13G	Page 6 of 9
Item 1(a).	Name of Issuer:		
	Catalyst Pharmace	uticals, Inc.	
Item 1(b).	Address of Issuer's	Principal Executive Offices:	
	355 Alhambra Circ Coral Gables, Flor		
Item 2(a).	Name of Person Fi	ling:	
	James E. Flynn, De	eerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P.	
Item 2(b).	Address of Princip	al Business Office, or if None, Residence:	
	James E. Flynn, Do New York, NY 100	eerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P., 345	5 Park Avenue South, 12th Floor,
Item 2(c).	Citizenship:		
	Deerfield Mgmt, L	.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P Delaware limited p	partnerships;
	James E. Flynn – U	United States citizen	
Item 2(d).	Title of Class of Se	ecurities:	
	Common Stock		
Item 2(e).	CUSIP Number:		
	14888U101		_
Item 3.	If This Statement i	s Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:	
(a)	☐ Broker or de	aler registered under Section 15 of the Exchange Act.	
(b)	☐ Bank as defi	ned in Section 3(a)(6) of the Exchange Act.	
(c)	☐ Insurance co	mpany as defined in Section 3(a)(19) of the Exchange Act.	
(d)	☐ Investment o	company registered under Section 8 of the Investment Company Act.	
(e)	☐ An investme	nt adviser in accordance with Rule 13d-1(b)(1)(ii)(E);	
(f)	☐ An employe	e benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);	
(g)	☐ A parent hol	ding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);	

Deerfield Mgmt, L.P. - 5,884,448

Deerfield Partners, L.P. - 5,884,448 James E. Flynn - 5,884,448

Deerfield Management Company, L.P. - 5,884,448

Shared power to dispose or to direct the disposition of:

(iv)

^{**}See footnotes on cover pages which are incorporated by reference herein.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following \Box .

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit B

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certifications.

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: <u>/s/ Jonathan Isler</u>

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

Date: February 10, 2023

Exhibit List

Exhibit A. Joint Filing Agreement.

Exhibit B. Item 8 Statement.

Exhibit C. Power of Attorney (1).

(1) Power of Attorney previously filed as Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.

Joint Filing Agreement

The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Catalyst Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.

DEERFIELD MGMT, L.P.

By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Flynn Management LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

DEERFIELD PARTNERS, L.P.

By: Deerfield Mgmt, L.P., General Partner By: J.E. Flynn Capital, LLC, General Partner

By: /s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

JAMES E. FLYNN

/s/ Jonathan Isler

Jonathan Isler, Attorney-In-Fact

Exhibit B

Due to the relationships between them,	the reporting persons hereunder m	ay be deemed to constitute a	"group"	with one another for pur	rposes of
Section 13(d)(3) of the Securities Exchange Act	of 1934.				